Literature DB >> 15363831

Reactive oxygen species in hypertension; An update.

Bernard Lassègue1, Kathy K Griendling.   

Abstract

Hypertension is associated with an elevation of reactive oxygen species (ROS) and frequently also with an impairment of endogenous antioxidant mechanisms. Experimental manipulation of the redox state in vivo shows that ROS can be a cause of hypertension. During the development of the disease, ROS are generated by endogenous sources, notably the NADPH oxidase enzyme family and uncoupled nitric oxide synthase, due to a mutual reinforcement between ROS and humoral factors. The ROS affect multiple tissues, either directly or through nitric oxide depletion. In the vasculature, they induce contraction and endothelial dysfunction. In blood vessels and myocardium, they cause hypertrophic remodeling. In the kidneys, ROS promote salt reabsorption, decrease glomerular filtration, and lead to tissue damage. Finally, they also increase efferent sympathetic activity from the central nervous system. Progress in our understanding of the mechanisms of ROS formation and their plethora of pathophysiologic effects is expected to lead from simple antioxidant therapy to specific antihypertensive treatments. Copyright 2004 American Journal of Hypertension, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363831     DOI: 10.1016/j.amjhyper.2004.02.004

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  88 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

2.  Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways.

Authors:  Thomas Kampfrath; Andrei Maiseyeu; Zhekang Ying; Zubair Shah; Jeffrey A Deiuliis; Xiaohua Xu; Nisharahmed Kherada; Robert D Brook; Kongara M Reddy; Nitin P Padture; Sampath Parthasarathy; Lung Chi Chen; Susan Moffatt-Bruce; Qinghua Sun; Henning Morawietz; Sanjay Rajagopalan
Journal:  Circ Res       Date:  2011-01-27       Impact factor: 17.367

3.  Aldosterone stimulates superoxide production in macula densa cells.

Authors:  Xiaolong Zhu; R Davis Manning; Deyin Lu; Celso E Gomez-Sanchez; Yiling Fu; Luis A Juncos; Ruisheng Liu
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

4.  Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension.

Authors:  Alfonso Mate; José L Miguel-Carrasco; María T Monserrat; Carmen M Vázquez
Journal:  J Physiol Biochem       Date:  2010-05-27       Impact factor: 4.158

Review 5.  Reactive oxygen species and vascular remodelling in hypertension: still alive.

Authors:  Shaoping Xu; Rhian M Touyz
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

Review 6.  Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system.

Authors:  Bernard Lassègue; Alejandra San Martín; Kathy K Griendling
Journal:  Circ Res       Date:  2012-05-11       Impact factor: 17.367

Review 7.  Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species.

Authors:  Catharine I Whiteside
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

8.  Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats.

Authors:  Y Alvarez; A M Briones; R Hernanz; J V Pérez-Girón; M J Alonso; M Salaices
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 10.  Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD.

Authors:  Zhenyu Qin; Krzysztof J Reszka; Tohru Fukai; Neal L Weintraub
Journal:  Transl Res       Date:  2007-11-08       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.